Recently, a clinical trial (NCT02541370) exploring the activity of CD133-guided CAR T cells in various cancers, including HCC, has been accomplished, showing the safety and efficacy of CD133-targeted CAR T-cells in HCC patients [123,124]. The gene discussed is PROM1; the disease is cancer.